Complix
complix.com
Drug Discovery
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Our company Complix is a biopharmaceutical company developing a pipeline of transformative Alphabody based therapeutics against a number of cutting-edge and challenging disease targets that play an important role in viral diseases, oncology and autoimmunity About us Alphabodies are transformative biotherapeutics designed and created to address important disease targets that are considered "undruggable" by existing therapeutics.
News
Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases
/PRNewswire/ -- Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, today announced that it has signed a...
Read more
Report
Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases
/PRNewswire/ -- Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, today announced that it has signed a...
Read more
Report
Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases
Hasselt, July 28, 2021 - Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics, today announced that it has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co., one of Chin
Read more
Report
Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances
Publication highlights for the first time a cell-penetrating protein drug with high affinity target binding, exquisite specificity, and extended half-life in vivo Transformative, "membrane crossing" CPAB technology designed to address multiple challenging
Read more
Report
Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances
Read more
Report
Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets
Complix retains joint development and commercialization rights outside Greater China Complix to receive upfront fees and research funding as well as potential milestone and royalty payments Hasselt, March 10, 2021 - Complix, a biopharmaceutical company de
Read more
Report
Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets
/PRNewswire/ -- Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant...
Read more
Report
Complix receives €1.2 million VLAIO grant to develop a novel and differentiated class of anti-Covid-19 Alphabody therapeutics
Anti-viral Alphabodies act by inhibiting viral cell fusion New class of Alphabodies with prophylactic and therapeutic potential Hasselt, Belgium, October 7, 2020 - Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody ther
Read more
Report
Complix to Present Progress on its Pipeline of Cell Penetrating Alphabodies at BioEquity Europe 2019
Hasselt, May 8, 2019 - Complix, a biopharmaceutical company developing Cell Penetrating Alphabodies (CPABs) to target intracellular disease targets, announces that its Chief Executive Officer, Dr Mark Vaeck, will be presenting at the 20th Annual BioEquity
Read more
Report
Complix to Present its Cell Penetrating Alphabodies Acting on Important Intracellular Targets at PEGS Europe 2018
Hasselt, November 12, 2018 - Complix, a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabodies (CPABs) announces that its Chief Scientific Officer, Dr Yvonne McGrath, will be presenting recent developments on CPABs
Read more
Report
Show more news